Biosimilars Market Research Reports & Industry Analysis

Biosimilars (otherwise termed follow-on-biologics, or FOBs for short) stand for the versions of biopharmaceuticals, which have the resembling but not identical parent molecule, and are created either by living organisms or from living micro-organisms by way of rDNA (recombinant DNA) or supervised gene expression technologies. The approval of Biosimilars occurs via strictly defined regulatory paths based on whether FOBs have shown comparability with their reference substance.

The worldwide Biosimilars Market is anticipated to surpass a EUR 14.9bn mark by end 2018. The major drivers encompass cost efficiency of biosimilars versus their high-priced analogues, the enlarging thirst for biotechnology drugs, imminent biotech drugs’ patent expiries, the planet’s aging population, and the rising frequency of critical illnesses. The illustrious actors on the global Biosimilars stage encompass Biocon, Intas Biopharmaceuticals, Cipla, Biopartners, Hospira, Wockhardt, Teva Pharmaceutical Industries, Sandoz International, amidst others.

The Catalogue’s research reports offer world, region and nation-wise analyses of the Biosimilars Market development over various time periods. The researches are lavish with discussions of the Biosimilars Industry growth rate, structure and capacity. The market trends, growth obstacles/stimulators, key products and those in R&D stage, and more issues are studied in the reports. Additionally, the research reports indicate and profile the leading players and hoped-for entrants, and offer market projections and forecasts.

Found 110 publications
Global Biosimilar Market: Size, Trends & Forecasts (2016-2020) US$ 800.00

... “Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)”, provides an analysis of global biosimilar market in terms of value. The report also provides a brief analysis of the global biologics market by value and market share ... current and future trends. Sandoz, Amgen, Celltrion and Pfizer are some of the key players operating in the global biosimilar market whose company profiling ...

Nov, 2016 58 pages
Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update US$ 1,393.00 US$ 1,115.00

... about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar ... , pavilizumab, tocilizumab, and ustekinumab. Download sample pages of Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update Competitor projects are listed in a tabular format providing information ...

May, 2016 462 pages
Global and Chinese Biosimilars Industry, 2016 Market Research Report US$ 2,800.00

... 'Global and Chinese Biosimilars Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Biosimilars industry with a focus on the Chinese market ... a new project of Biosimilars Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2011-2021 global and Chinese Biosimilars industry covering all important ...

Nov, 2016 150 pages
Remicade (Infliximab) Biosimilar Clinical Trial Insight US$ 1,200.00

... location. “Remicade (Infliximab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 17 biosimilar version of Remicade drug in clinical pipeline. Currently there are 2 biosimilars in Phase-III trials and are ...

Oct, 2016 50 pages
Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight US$ 1,000.00

... on the location. “Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially ...

Oct, 2016 35 pages
Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight US$ 1,500.00

... Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials ...

Oct, 2016 85 pages
Humira Biosimilars Clinical Trial Insight US$ 1,500.00

... Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials ...

Oct, 2016 80 pages
Enbrel Biosimilars Clinical Trial & Opportunity Insight US$ 1,500.00

... Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilar version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials ...

Oct, 2016 70 pages
Global Biosimilars Market, 2015 - 2025 US$ 2,199.00

The ‘Global Biosimilars Market, 2015 - 2025’ report provides an extensive study of the rapidly growing biosimilars market. With the blockbuster biologics losing patent protection and biotechnology ... the key growth drivers and restraints to the biosimilars market. Some of the primary market drivers include growing healthcare expenses and impending patent ...

Jul, 2015 462 pages
Global Biosimilars Market and Forecast (By Product Type, Applications, Country Wise and Companies) to 2021 and Biosimilars Approved and Pipeline Analysis US$ 1,350.00

... 1. Global Biosimilars Market and Forecast - By Product Type 2. Global Biosimilars Market and Forecast - By Applications 3. Global Biosimilars Market and Forecast - By Country Wise 4. Global Biosimilars Company - Profile, Revenue, Approved and Pipeline Biosimilars Analysis 5. Country with Biosimilar Guideline ...

Oct, 2016 177 pages
EPO Biosimilars - The Future of Erythropoietin Market US$ 600.00

... . However, the biosimilar versions of these drugs are expected to witness precipitous growth owing to their low cost. As per RNCOS report “EPO Biosimilars - The ... segmented into biologic and biosimilar erythropoietin markets. The report also highlights the various biologic and biosimilar erythropoietin drugs currently available ...

Aug, 2016 45 pages
Analyzing the Global Biosimilars Industry 2016 US$ 1,100.00

... of biosimilars is growing. Aruvian Research analyzes the global biosimilars industry in its research report Analyzing the Global Biosimilars Industry 2016. In this research report, we analyze what biosimilars are ... nature of biosimilars and the types of biologics available and role of biosimilars are also analyzed, along with the importance of biosimilars and a comparison between biosimilars and ...

Jul, 2016 285 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update US$ 560.00

Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update Humira, Enbrel and Remicade ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May, 2016 124 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update US$ 335.00

Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-Her2 Antibodies 2016 updates the ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May, 2016 84 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update US$ 280.00

Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update This Competitive Intelligence report about Biosimilar and Biosuperior Anti-EGF-R Antibodies updates the competitive ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May, 2016 56 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update US$ 335.00

Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-CD20 Antibodies 2016 updates the ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May, 2016 74 pages
Biosimilars in Oncology: Update Bulletin [Feb 2016] US$ 995.00

... on the latest events that have the potential to shape the oncology biosimilars market. Topics covered include opinions about data from Sandoz ... drive down prices to unsustainable levels and cause the biosimilars market in the US to fail? Update Bulletins include expert insight and analysis based on FirstWord ...

Feb, 2016
Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors US$ 220.00

Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors This Competitive Intelligence report titled PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors“ provides a competitor evaluation in the field of protein- and peptide-based agonists of the parathyroid hormone (PTH) receptor ...

Feb, 2016 32 pages
Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update US$ 440.00

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update The Competitive Intelligence Report Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update“ provides a competitor evaluation in the field ...

Feb, 2016 46 pages
Biosimilars in Oncology: KOL Insight US$ 7,900.00

... to accept biosimilars of proven targeted treatments. So what do pharma companies need to do to increase confidence and ensure uptake of biosimilars in this toughest of markets? Biosimilars in Oncology: KOL Insight spells out the concerns about equivalence, evidence and endpoints with insights into the current ...

Jan, 2016
Biosimilars: Regulatory Outlook US$ 2,100.00

... significant regulatory progress has been made in recent years, clarity is distinctly lacking on certain issues, such as interchangeability and naming.  FirstWord’s Biosimilars: Regulatory Outlook provides insight and opinion on why. This 64 page report gives in-depth and candid views on what eight industry and biosimilar experts ...

Nov, 2015
US Biosimilars Market Opportunity & Clinical Pipeline Analysis US$ 2,400.00

... Biosimilars Market Impact of Biosimilars in US Market Impact of Reimbursement Policies on US Biosimilars Market Zarxio: First Approved Biosimilar in US US Biosimilar Clinical Pipeline By Company, Indication & Phase US Biosimilar Clinical Pipeline: 104 Biosimilars Marketed Biosimilars: 1 Biosimilar ...

Feb, 2016 330 pages
Biosimilars Market: By Product (Recombinant Glycosated Proteins, Others) Technology (Chromatography, Mass Spectroscopy, Electrophoresis, Others) Application (Blood & Oncology Diseases,... US$ 5,250.00 US$ 4,200.00

... drugs also increase leading to increase in biosimilars market. The global market for the biosimilars is segmented into different product types by technology and application. Each of these ... and comprehensive analysis of biosimilars market Regulations for biosimilars play a vital role as they maintain a balance between original & biosimilar products. Currently the geographic biosimilar market is segmented into ...

Aug, 2015 86 pages
Japan Biosimilar- Active Players In Quest of a Specialty & Niche BS space US$ 4,000.00 US$ 3,400.00

... with Celltrion-NK Remicade biosimilar in 2014/2015 in the Japan pharma market demonstrated more flexibility for EU- Ex-Japan data by JP regulatory ... specialty therapy area- like ophthalmology BS (Lucentis), Enzyme therapy BS (JCR) In this report, we attempt to analyze trend/requirement of regulatory approval of ...

Jan, 2016 101 pages
Global Biosimilars Sales 2015 Market Research Report US$ 4,000.00

The Global Biosimilars Sales 2015 Market Research Report is a professional and in-depth study on the current state of the Biosimilars market. The report provides a basic overview of the Biosimilars industry ... the global Biosimilars market size (volume and value), and the sales segment market is also discussed by product type, application and region. The major Biosimilars market (including ...

Dec, 2015 162 pages
Europe Biosimilars Market Opportunity Outlook 2020 US$ 2,400.00

... European biosimilars market. “Europe Biosimilars Market Opportunity Outlook 2020” Report Highlight: Europe Biosimilars Market Outlook Europe Biosimilars Market Trend Analysis by Country Introduction of Biosimilars in European Market by Segment Clinical & Non Clinical Guidelines Europe Biosimilar ...

Nov, 2015 310 pages
World Biosimilars/Follow-on-Biologics - Market Opportunities and Forecast, 2014 - 2020 US$ 4,740.00

... data about changing market trends, competition and opportunities in biosimilars market are provided in the ... market dynamics Identification of key investment pockets in the biosimilars market would help the stakeholders in making informed decisions Key Deliverables Global biosimilars/follow-on-biologics market ...

Sep, 2015 120 pages
Analysis of USFDA's Approval of Biosimilars Case in Focus: Zarxio (Biosimilar of Amgens Neupogen) US$ 1,000.00

... Regulations around approval biosimilars in the US An overview of global biosimilar market Case study on the US approval of Zarxio (Biosimilar of Amgen’s ... Business Portfolio Planning Strategic/Business Analysis Business Development Licensing Technical Analysis Portfolio Management/Planning Project Management ...

Sep, 2015
Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis US$ 460.00

Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis The Competitive Intelligence report Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis describes product ... G-CSF products represent an attractive market size for biosimilar proteins in regulated markets. Biosimilar filgrastim products have already been introduced into the the ...

Jul, 2015 76 pages
Global Biosimilars Industry 2015 Market Research Report US$ 2,850.00

2015 Global Biosimilars Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Biosimilars industry, focusing on the main regions ... with: 1.) basic information; 2.) the Asia Biosimilars industry; 3.) the North American Biosimilars industry; 4.) the European Biosimilars industry; 5.) market entry and investment feasibility; and ...

Jul, 2015 170 pages
Global & USA BioSimilar Market Analysis to 2021; BioBetters, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte Colony-Stimulating Factor (G-CSF), Anti-Tumor Necrosis Factor... US$ 3,400.00 US$ 2,720.00

... biosimilars into the U.S., which happens to be the largest market for biopharmaceuticals. This report provides a comprehensive overview of the size of biosimilars’ market, the segmentation of the market ...

Aug, 2015 271 pages
The Future of Biosimilars 2016 US$ 2,195.00

... Understand the Forces Shaping the Biosimilars Market Commercialisation: Differentiation may be the key success factor for biosimilars. Discover the strategies manufacturers ... biosimilars in Europe shaped attitudes toward switching both treatment-naïve and established patients to biosimilars? Getting crowded: How will the market handle multiple biosimilars ...

Jul, 2016
Physician Views: Will Patient Switching Studies Support Biosimilar Adoption? US$ 695.00

... market will at some point provide a secondary benchmark for biosimilar developers, physicians, patients and payers, when data from a much anticipated 500-patient switching study ... in the EU5 the following questions this week… Has your view towards current/future usage of biosimilar TNF inhibitors become more ...

Jun, 2015
BIOSIMILARS - Regulatory Framework and Pipeline Analysis US$ 2,995.00 US$ 2,396.00

BIOSIMILARS - Regulatory Framework and Pipeline Analysis Summary Biosimilars are copied versions of biologics that offer a 20-50% reduction in cost compared with innovative biologic products. Biosimilars are ... dynamics: Trends, Drivers, and Barriers WHO guidance for biosimilars Regulatory overview, biosimilar guidelines, regulatory framework for biosimilars, and market outlook for: Europe, USA, India ...

Jun, 2015 94 pages
Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars US$ 750.00

... latest Chinese guidance for development, evaluation, license approval of biosimilars, Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars provided a comprehensive and thorough knowledge of the latest Chinese guidance for development, evaluation, license approval of biosimilars ...

May, 2015 48 pages
Evolution of Technologies for Therapeutic Antibodies-From mAbs to Biosimilars US$ 1,999.00

The report provides in-depth information on technologicial platforms being developed for monoclonal antibodies and how they have been improvised for biosimilar development. Also various issues pertaining to manufacturing of biosimilars have been highlighted with possible solutions to to address the hurdles.

Jan, 2015 64 pages
Physician Views: Oncologists React to Approval of Zarxio – the First US Biosimilar US$ 695.00

... for. FirstWord polled US-based oncologists on this issue, among others, following the ODAC meeting in January (see Physician Views Poll Results: Positive FDA sentiment for biosimilar Neupogen shared by oncologists). While Zarxio is a trailblazer in the ...

Mar, 2015
Physician Views: CMS Guidance on Biosimilar Reimbursement – What Do Oncologists and Rheumatologists Think? US$ 695.00

... physician sentiment to the CMS guidance. In our first poll, focused on Part B reimbursement, we are asking oncologists… How effective they expect the CMS reimbursement guidance to be in incentivising physicians ... of 'de-facto' interchangeability via CMS guidance Their view on interchangeability status for ...

Apr, 2015
Biosimilars: US Payer Perspectives US$ 2,100.00

... from some leading investment banks claiming that biosimilars in the US are on the cusp of greatness. Biosimilars: US Payer Perspectives provides a much needed tonic to perhaps the overly optimistic sentiment that has seeped into the discussions about the US biosimilars opportunity ...

Apr, 2015
Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors US$ 1,500.00

Competitor Analysis: The rapeutic Antibodies 2015: Biosimilars & Biosuperiors This Competitive Intelligence Report about The rapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor ...

Apr, 2015 414 pages
Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders US$ 6,900.00

... , Spain and Italy, Medical Affairs Reputations (EU5): Biosimilar mAbs in Inflammatory Disorders offers insights on how Medical Affairs teams from companies developing and marketing biosimilar anti-TNF monoclonal ... , Spain, the UK; EU5 – biosimilar mAb developers and companies marketing branded mAbs require solid evidence upon which to base medical affairs’ strategy for their ...

Feb, 2015
Biosimilars: European Payer Perspectives (2016) US$ 695.00

... the biosimilar industry do to help its cause? This report identifies the issues that payers identify as critical to the continued growth and adoption of biosimilars. Biosimilars: European Payer Perspectives is informed with candid insights of 15 European payers from the five leading European markets ...

Jan, 2016
Biosimilars (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 US$ 3,495.00 US$ 2,796.00

Biosimilars (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 SUMMARY Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the ... Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Biosimilars including ...

Dec, 2014 82 pages
2015 Deep Research Report on Global Biologics and Biosimilars Industry US$ 2,600.00

2015 Deep Research Report on Global Biologics and Biosimilars Industry is a professional and ... analysis, investment return analysis, and development trend analysis. In conclusion, it is a deep research report on Global Biologics and Biosimilars industry. Here, we express ...

Feb, 2015 170 pages
Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin US$ 390.00

Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin This Competitive Intelligence Report about Her2 Antibodies 2015 - Biosimilars and ... and make out about 81% of the franchise sale. Therefore, the Her2 antibody market is not only highly attractive for biosimilar developments ...

Feb, 2015 64 pages
Competitor Analysis: VEGF & VEGF-R Antibodies 2015 – Biosimilars and Biosuperiors of Avastin and Lucentis US$ 460.00

Competitor Analysis: VEGF & VEGF-R Antibodies 2015 – Biosimilars and Biosuperiors of Avastin and Lucentis This Competitive Intelligence Report about VEGF and VEGF-R ... more cancer and eye disease indications. The commercial success of the VEGF antibodies and the expiry of patent protection has laid the ground ...

Feb, 2015 79 pages
Global Biosimilar Market Trends & Opportunities: 2015 Edition US$ 800.00

... “Global Biosimilar Market: Trends & Opportunities (2015 Edition)” analyzes the global biologics market, with exhaustive discussion on demand of Biosimilars with increase in patent expiry of innovator drugs. The key market ... titled “The Global Biosimilar Market: Trends & Opportunities (2014-2018)” provides an in-depth analysis of the growing Biosimilar Market with detailed analysis of market sizing and growth, market share and ...

Jan, 2015 80 pages
New Phase of Mab biosimilar knocks the door Biosimilar Opportunities In Japan US$ 4,000.00 US$ 3,400.00

... Japan biosimilar market. Consolidation activities are in place for biosimilar entry by a couple of big players (Daiichi-Sankyo, KHK), JP Innovator+ GE companies (Meiji, Fujifilm, Nippon Kayaku, Mochida, and Kissei ...

Jan, 2015 65 pages
Physician Views: What opportunity for biosimilar basal insulin? US$ 695.00

... have historically had minimal opportunity to leverage discounts from an oligopolistic ... well established players, it remains to be seen how comfortable physicians would be using a 'biosimilar' insulin developed by ... as 'interchangeable' with branded Lantus). Similarly, what percentage of patients would you be ...

Nov, 2014
Physician Views: Biosimilar Lucentis – what opportunity? US$ 695.00

... Lucentis, while the availability of compounded Avastin, used as an alternative to Lucentis at a much cheaper cost, adds further confusion to the market outlook. Furthermore, a Physician Views ... therapies persists). FirstWord's Biosimilar Index reveals just one biosimilar Lucentis product in development; PF582 ...

Oct, 2014
1 2 3 >
Skip to top